Invanz is a once-daily injectable antibiotic approved for use in adults for the treatment of moderate to severe infections caused by common gram-positive and gram-negative aerobic and anaerobic bacteria. Included, are community-acquired pneumonia, intra-abdominal, skin, urinary tract, kidney and post-surgical gynecological infections.
Prior to administration, Invanz must be reconstituted and diluted.
The approval of Invanz is supported by studies conducted in more than 1,900 subjects, in five infectious disease categories. Treatment ranged from three to 14 days. Invanz exhibited an excellent safety profile and showed success rates equivalent to those of comparator antibiotics.
Adverse events associated with the use of Invanz may include (but are not limited to) the following:
Invanz (ertapenem sodium) is a structurally unique 1-(beta) methyl-carbapenem related to a class of antibiotics known as beta-lactams, which includes penicillins and cephalosporins. Invanz works by blocking the formation of bacterial cell walls, thereby causing cell death.
For additional information on Invanz, please visit Invanz.
The Invanz drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.